Use of Hormone Replacement Therapy for Menopause (HRT) in Kidney Disease

Chronic kidney disease (CKD) affects a significant proportion of the global population, with a higher prevalence in women than men. The intersection of CKD and menopause introduces unique challenges in managing symptoms of oestrogen deficiency while considering the implications for renal health.

Hormone Replacement Therapy (HRT), known for its efficacy in alleviating vasomotor symptoms and improving quality of life, has sparked interest and debate regarding its suitability for women with CKD. This article explores the current evidence on the use of HRT in this population, balancing risks and benefits within the context of the British Menopause Society (BMS) guidelines.

Kidney Disease, HRT and Menopause Treatments

The Menopausal Transition and CKD

Menopause is associated with a decline in oestrogen, progesterone and testosterone levels, leading to variety of perimenopausal symptoms. Additionally, menopause is linked to an accelerated risk of cardiovascular disease (CVD), osteoporosis, and cognitive decline. Women with CKD experience these issues in tandem with CKD-specific complications, such as increased CVD risk, mineral and bone disorders, and anaemia. Therefore, the management of menopause in CKD patients requires a nuanced approach.

Pathophysiological Considerations

Chronic kidney disease alters the pharmacokinetics of various drugs due to impaired renal clearance and changes in protein binding. These factors are critical when considering treatment of the menopause with HRT, as they may influence the metabolism of oestrogen and progestogens. Moreover, CKD-associated comorbidities, including hypertension and CVD, necessitate a careful assessment of HRT’s safety profile.

Benefits of HRT for menopause in Women with kidney disease

1. Bone Health: Women with CKD are at heightened risk of osteoporosis due to secondary hyperparathyroidism and oestrogen deficiency. HRT has been shown to improve bone mineral density (BMD) and reduce fracture risk in postmenopausal women without CKD (1). While evidence specific to CKD is limited, the potential benefits in this domain warrant consideration.

2. Cardiovascular Health: Transdermal oestrogen has been associated with a lower risk of thromboembolism compared to oral formulations (2). In CKD, where vascular calcification and endothelial dysfunction are prevalent, this route may offer a safer alternative.

3. Quality of Life: HRT significantly alleviates vasomotor symptoms and improves sleep, mood, and overall quality of life in postmenopausal women (3). For women with CKD, these benefits could positively impact disease-related fatigue and mental health.

Risks of HRT in CKD

1. Thromboembolic Risk: CKD is an independent risk factor for venous thromboembolism (VTE). Oral oestrogens may exacerbate this risk, necessitating a preference for transdermal formulations, which bypass hepatic metabolism.

2. Progression of CKD: Limited evidence suggests that oestrogen may have renal protective effects in some contexts, but high doses or inappropriate formulations could theoretically worsen proteinuria or blood pressure control.

3. Breast Cancer Risk: The association between HRT and breast cancer is dose- and duration-dependent (4). This risk must be contextualised within the patient’s overall health profile.

4. 
   

Individualised Approaches to HRT

The BMS advocates for a personalised approach to HRT, considering the individual’s symptom severity, comorbidities, and preferences. For women with CKD, this includes:

1. Route of Administration: Transdermal patches or gels are preferred to minimise thrombotic risk and avoid hepatic first-pass metabolism.

2. Monitoring: Regular assessments of renal function, blood pressure, and markers of CVD risk are essential.

3. Choice of Progestogen: Micronised progesterone is often favoured for its lower metabolic impact and better safety profile.

   
   

Knowledge Gaps and Future Directions

Despite the potential benefits, robust clinical trials evaluating the safety and efficacy of HRT specifically in women with CKD are lacking. Observational studies suggest that transdermal oestrogen may be beneficial, but further research is needed to establish definitive guidelines. Collaboration between nephrologists and menopause specialists is crucial to optimise care for this population.

Conclusion

The use of HRT for the menopause in women with kidney disease requires a careful, individualised approach. Transdermal oestrogen combined with appropriate progestogens may offer symptom relief and systemic benefits while minimising risks. However, ongoing research and multidisciplinary management remain critical to addressing the unique challenges faced by this group. By adhering to evidence-based practices, clinicians can empower women with CKD to make informed decisions about their menopausal care.

Book a Menopause Consultation

References

1. Cauley JA, et al. "Estrogen and bone health in postmenopausal women." New England Journal of Medicine. 2014;370(5):512-520.

2. Canonico M, et al. "Impact of oestrogen routes of administration on thromboembolism risk." Circulation. 2016;133(16):1489-1500.

3. Baber RJ, et al. "The impact of HRT on quality of life in menopausal women." Maturitas. 2020;135:1-9.

4. Collaborative Group on Hormonal Factors in Breast Cancer. "Breast cancer and hormone replacement therapy." The Lancet. 2019;394(10204):1159-1168.